Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 316

Results For "IND"

6837 News Found

Zydus Wellness launches pilot for ready-to-drink beverage Glucon-D Activors
News | May 06, 2024

Zydus Wellness launches pilot for ready-to-drink beverage Glucon-D Activors

The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness


Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake
News | May 03, 2024

Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake

The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market


Novartis to acquire Mariana Oncology for upfront US$ 1 billion
News | May 03, 2024

Novartis to acquire Mariana Oncology for upfront US$ 1 billion

Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications


Moderna posts Q1 2024 revenues at US$167 million
News | May 03, 2024

Moderna posts Q1 2024 revenues at US$167 million

GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)


FDA grants full approval for TIVDAK to treat cervical cancer
Drug Approval | May 02, 2024

FDA grants full approval for TIVDAK to treat cervical cancer

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer


Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine
Clinical Trials | May 02, 2024

Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases


Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion
News | May 02, 2024

Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter


Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
News | May 01, 2024

Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion

2024 full-year revenue guidance raised by US$ 2 billion


Gland Pharma appoints Satnam Singh Loomba as COO
People | April 29, 2024

Gland Pharma appoints Satnam Singh Loomba as COO

Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.